Efficacy and safety of 0.05% ingenol mebutate in the treatment of basal cell carcinoma: A prospective study-Reference-Cited by-同舟云学术

Efficacy and safety of 0.05% ingenol mebutate in the treatment of basal cell carcinoma: A prospective study

Published:2022-08-10 Issue:2 Volume:3 Page:
ISSN:2690-442X
Container-title:Skin Health and Disease
language:en
Short-container-title:Skin Health and Disease

Author:

Velin Marine¹,Cardot‐Leccia Nathalie²,Cathelineau Anne‐Claire³,Duteil Luc³,Queille‐Roussel Catherine³,Passeron Thierry¹⁴,Bahadoran Philippe¹⁴^ORCID

Affiliation:

1. Department of Dermatology Université Nice Côte d’Azur CHU Nice Nice France

2. Department of Pathology Université Nice Côte d’Azur CHU Nice Nice France

3. CPCAD (Center of Clinical Pharmacology Applied to Dermatology) Archet 2 Hospital Nice France

4. INSERM U1065 Centre Méditerranéen de Médecine Moléculaire Université Nice Côte d’Azur Nice France

Publisher

Wiley

Subject

General Computer Science

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ski2.150

Reference5 articles.

1. Basal cell carcinoma

2. Interventions for basal cell carcinoma of the skin;Thomson J;Cochrane Database Syst Rev,2020

3. Characterisation of the inflammatory response triggered by topical ingenol mebutate 0.05% gel in basal cell carcinoma

4. European Medicines Agency.EMA review of Picato concludes medicine's risks outweigh its benefits;2020. Available from:https://www.ema.europa.eu/en/news/ema‐review‐picato‐concludes‐medecines‐risks‐outweigh‐its‐benefitshuman/referrals/picato

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Why Is Wnt/β-Catenin Not Yet Targeted in Routine Cancer Care?;Pharmaceuticals;2024-07-16

2. Skin cancer special issue in Skin Health and Disease;Skin Health and Disease;2023-03-10